Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury

References

• Burke D, Fullen BM, Stokes D, Lennon O. Eur neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. J Pain 2017;21(1):29–44. doi:10.1002/ejp.905.
   Web of Science ®Google Scholar
• Hagen EM, Rekand T. Management of neuropathic pain associated with spinal cord injury. Pain Ther 2015;4(1):51–65. doi:10.1007/s40122-015-0033-y.
   PubMed Web of Science ®Google Scholar
• Shiao R, Lee-Kubli CA. Neuropathic pain after spinal cord injury: challenges and Research perspectives. Neurotherapeutics 2018;15(3):635–53. doi:10.1007/s13311-018-0633-4.
   PubMed Web of Science ®Google Scholar
• DeFrates S, Cook AM. Pharmacologic treatment of neuropathic pain following spinal cord injury. Orthopedics 2011;34(3):203. doi:10.3928/01477447-20110124-19.
   PubMed Web of Science ®Google Scholar
• Teasell RW, Mehta S, Aubut JA, Foulon B, Wolfe DL, Hsieh JT, Townson AF. Short C; spinal cord injury rehabilitation Evidence Research team. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil 2010;91(5):816–31. doi:10.1016/j.apmr.2010.01.022.
   PubMed Web of Science ®Google Scholar
• Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. Korean J Pain 2020;33(1):3–12. doi:10.3344/kjp.2020.33.1.3.
   PubMed Web of Science ®Google Scholar
• Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014 Jun;28(6):491–6. doi:10.1007/s40263-014-0164-4.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs 2017;77(4):403–26. doi:10.1007/s40265-017-0700-x.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs 2021;81(1):125–56. doi:10.1007/s40265-020-01432-7.
   PubMed Web of Science ®Google Scholar
• Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92(1–2):147–57. doi:10.1016/s0304-3959(00)00482-6.
   PubMed Web of Science ®Google Scholar
• Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004 Oct;5(8):427–32. doi:10.1016/j.jpain.2004.07.001.
   PubMed Web of Science ®Google Scholar
• Güleç G, Köşger F, Eşsizoğlu A. DSM-5'te Alkol ve madde kullanım bozuklukları. Alcohol and substance use disorders in DSM-5. Psikiyatr Güncel Yaklaşımlar/Curr Approaches Psychiatry 2015;7(4):448–60. doi:10.5455/cap.20150325081809.
   Google Scholar
• Hägg S, Jönsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf 2020;43(12):1235–54. doi:10.1007/s40264-020-00985-6.
   PubMed Web of Science ®Google Scholar
• Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction 2019;114(6):1026–34. doi:10.1111/add.14412.
   PubMed Web of Science ®Google Scholar
• Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M. French addictovigilance network (FAN). gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry 2021;12:639780. doi:10.3389/fpsyt.2021.639780.
   PubMed Web of Science ®Google Scholar
• Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse, and diversion: a systematic review. Addiction 2016;111(7):1160–74. doi:10.1111/add.13324.
   PubMed Web of Science ®Google Scholar
• Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf 2015;10(2):184–6. doi:10.2174/1574886309666141022101956.
   PubMedGoogle Scholar
• Ashwini S, Amit DR, Ivan NS, Alka PV. Pregabalin dependence with pregabalin induced intentional self-harm behavior: a case report. Indian J Psychiatry 2015;57(1):110–11. doi:10.4103/0019-5545.148550.
   PubMed Web of Science ®Google Scholar
• Wu LT, McNeely J, Subramaniam GA, Brady KT, Sharma G, VanVeldhuisen P, et al. DSM-5 substance use disorders among adult primary care patients: results from a multisite study drug and alcohol dependence. Drug Alcohol Depend 2017;179:42–6. doi:10.1016/j.drugalcdep.2017.05.048.
   PubMed Web of Science ®Google Scholar
• Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol 2019;85(6):1260–9. doi:10.1111/bcp.13892.
   PubMed Web of Science ®Google Scholar
• Ibiloye EA, Barner JC, Lawson KA, Rascati KL, Evoy KE, Peckham AM. Prevalence of and factors associated with gabapentinoid use and misuse among Texas Medicaid recipients. Clin Drug Investig 2021;41(3):245–53. doi:10.1007/s40261-021-01009-6.
   PubMed Web of Science ®Google Scholar
• Nicholson Perry K, Nicholas MK, Middleton J, Siddall P. Psychological characteristics of people with spinal cord injury-related persisting pain referred to a tertiary pain management center. J Rehabil Res Dev 2009;46(1):57–67.
   PubMedGoogle Scholar
• Norrbrink Budh C, Hultling C, Lundeberg T. Quality of sleep in individuals with spinal cord injury: a comparison between patients with and without pain. Spinal Cord 2005;43(2):85–95. doi:10.1038/sj.sc.3101680.
   PubMed Web of Science ®Google Scholar
• Mehta S, McIntyre A, Dijkers M, Loh E, Teasell RW. Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis. Arch Phys Med Rehabil 2014;95(11):2180–6. doi:10.1016/j.apmr.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European medicines agency’s “suspected adverse drug reactions” database. CNS Drugs 2016;30(7):647–54. doi:10.1007/s40263-016-0359-y.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the food and drug administration adverse events reporting system (FAERS). Res Soc Adm Pharm 2019;15(8):953–8. doi:10.1016/j.sapharm.2018.06.018.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49(10):661–9. doi:10.2165/11536200-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 2016;16(11):1263–77. doi:10.1080/14737175.2016.1202764.
   PubMed Web of Science ®Google Scholar
• Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol 2014;70(2):197–204. doi:10.1007/s00228-013-1594-5.
   PubMed Web of Science ®Google Scholar
• Schjerning O, Pottegård A, Damkier P, Rosenzweig M, Nielsen J. Use of pregabalin – a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry 2016;49(4):155–61. doi:10.1055/s-0042-101868.
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013;69(6):1335–42. doi:10.1007/s00228-012-1464-6.
   PubMed Web of Science ®Google Scholar
• Roche S, Blaise M. Pregabalin and risk of addiction: a new care issue? Encephale 2020;46(5):372–81. doi:10.1016/j.encep.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapies 2016;71(6):575–8. doi:10.1016/j.therap.2016.04.006.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. Int J Clin Pharm 2021;43(4):1055–64. doi:10.1007/s11096-020-01217-8.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017;27(12):1185–215. doi:10.1016/j.euroneuro.2017.
   PubMed Web of Science ®Google Scholar
• HERPC (Hull & East Riding Prescribing Committee). Guidelines for the prescribing of: the initiation, management and discontinuation of pregabalin and gabapentin prescribing for neuropathic pain in primary care. Prescribing Guideline: Pregabalin Gabapentin; 2016. p. 5.
   Google Scholar